Trial Profile
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Izuralimab (Primary)
- Indications Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Fibroma; Gastric cancer; Head and neck cancer; Liver cancer; Malignant fibrous histiocytoma; Malignant melanoma; Multiple myeloma; Nasopharyngeal cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Acronyms DUET-3
- Sponsors Xencor
- 08 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2023 According to Xencor media release, the company will will stop internal development of XmAb104 due to emerging data from Phase 1 expansion cohorts not meeting efficacy criteria for advancing the program. The Company will continue to support patients currently enrolled and being treated.
- 08 May 2023 According to Xencor media release, the company has opened an expansion portion in the study (Part C) to evaluate XmAb104 in combination with ipilimumab in patients with microsatellite stable or proficient mismatch repair colorectal cancer.